|
The chemotherapy-naive patient with metastatic colorectal cancer
Memorial Sloan-Kettering Cancer Center, New York, NY
Colorectal cancer (CRC) tends to manifest with clinical symptoms usually only after the underlying disease process is well advanced. The task for managing chemotherapy-naive patients with metastatic CRC is to develop a treatment strategy that is appropriate for their overall level of function, preexisting comorbidities, and treatment preferences. FOLFIRI and FOLFOX have become the two most common cytotoxic regimens used in practice today, with data strongly suggesting their essentially equal effectiveness in the front line. Patients should be advised, however, that certain toxicities are more likely with one regimen in comparison with the other.
| Commun Oncol 2007;4(suppl 2):5–7 | full text |  74 kb |